Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 1/2012

01-01-2012 | Original paper

Bodyweight and other correlates of symptom-detected breast cancers in a population offered screening

Authors: Anne Kricker, Tracey DiSipio, Jennifer Stone, Chris Goumas, Jane E. Armes, Dorota M. Gertig, Bruce K. Armstrong

Published in: Cancer Causes & Control | Issue 1/2012

Login to get access

Abstract

Objective

To determine the factors associated with symptom-detected breast cancers in a population offered screening.

Methods

We interviewed 1,459 Australian women aged 40–69, 946 with symptom-detected and 513 with mammogram-detected invasive breast cancers ≥1.1 cm in diameter about their personal, mammogram, and breast histories before diagnosis and reviewed medical records for tumor characteristics and mammogram dates, calculating ORs and 95% confidence intervals (CIs) for symptom- versus mammogram-detected cancers in logistic regression models.

Results

Lack of regular mammograms (<2 mammograms in the 4.5 years before diagnosis) was the strongest correlate of symptom-detected breast cancer (OR = 3.04 for irregular or no mammograms). In women who had regular mammograms (≥2 mammograms in the 4.5 years before diagnosis), the independent correlates of symptom-detected cancers were low BMI (OR < 25 kg/m2 vs. ≥ 30 kg/m2 = 2.18, 95% CI 1.23–3.84; p = 0.008), increased breast density (available in 498 women) (OR highest quarter vs. lowest = 3.50, 95% CI 1.76–6.97; p trend = 0.004), high-grade cancer, and a larger cancer (each p < 0.01). In women who did not have regular mammograms, the independent correlates were age <50 years, a first cancer, and a ≥2-cm cancer. Smoking appeared to modify the association of symptom-detected cancer with low BMI (higher ORs for low BMI in current smokers) and estrogen receptor (ER) status (higher ORs for low BMI in ER cancers).

Conclusion

Women with low BMI may benefit from a tailored approach to breast cancer detection, particularly if they smoke.
Literature
1.
Newcomer LM, Newcomb PA, Trentham-Dietz A et al (2002) Detection method and breast carcinoma histology. Cancer 95(3):470–477PubMedCrossRef
2.
Cheung S, Greenway N, Lagord C, Williams L, Kearns O, Lawrence G (2009) All breast cancers report. A UK analysis of all symptomatic and screen-detected breast cancers diagnosed in 2006. National Cancer Intelligence Network, NHS Cancer Screening Programmes
3.
International Agency for Research on Cancer (2002) Breast cancer screening. International Agency for Research on Cancer, Lyon
4.
Australian Institute of Health and Welfare (AIHW) (2006) Breast screen Australia monitoring report 2002–2003. AIHW (Cancer Series no. 32), Canberra
5.
Taylor R, Supramaniam R, Rickard M, Estoesta J, Moreira C (2002) Interval breast cancers in New South Wales, Australia, and comparisons with trials and other mammographic screening programmes. J Med Screen 9(1):20–25PubMedCrossRef
6.
Bennett RL, Sellars SJ, Moss SM (2011) Interval cancers in the NHS breast cancer screening programme in England, Wales and Northern Ireland. Br J Cancer 104(4):571–577PubMedCrossRef
7.
Australian Institute of Health and Welfare, National Breast Cancer Centre (2001) Breast cancer size and nodal status. AIHW, Canberra
8.
Porter PL, El-Bastawissi AY, Mandelson MT et al (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91(23):2020–2028PubMedCrossRef
9.
Kricker A, Newman B, Gertig DM, Goumas C, Armes J, Armstrong BK (2008) Why do large breast cancers still present in a population offered screening? Int J Cancer 123:2907–2914PubMedCrossRef
10.
Byng JW, Yaffe MJ, Jong RA et al (1998) Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics 18(6):1587–1598PubMed
11.
Simpson JA, English DR, MacInnis RJ, Gertig DM, Hopper JL, Giles GG (2007) A comparison of different methods for including ‘age at menopause’ in analyses of the association between hormone replacement therapy use and breast cancer. J Fam Plann Reprod Health Care 33(1):11–16PubMedCrossRef
12.
WHO expert committee on physical status (1995) Physical status: the use and interpretation of anthropometry: report of a WHO expert committee. World Health Organisation, Geneva
13.
Yasui Y, Potter JD (1999) The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 10(5):431–437PubMedCrossRef
14.
Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22(3):207–219PubMedCrossRef
15.
Australian Institute of Health and Welfare (AIHW) (2007) Breast screen Australia monitoring report 2003–2004. AIHW (Cancer Series no. 36), Canberra
16.
Bihrmann K, Jensen A, Olsen AH et al (2008) Performance of systematic and non-systematic (‘opportunistic’) screening mammography: a comparative study from Denmark. J Med Screen 15(1):23–26PubMedCrossRef
17.
Elmore JG, Carney PA, Abraham LA et al (2004) The association between obesity and screening mammography accuracy. Arch Intern Med 164(10):1140–1147PubMedCrossRef
18.
Kerlikowske K, Walker R, Miglioretti DL, Desai A, Ballard-Barbash R, Buist DS (2008) Obesity, mammography use and accuracy, and advanced breast cancer risk. J Natl Cancer Inst 100(23):1724–1733PubMedCrossRef
19.
Bartow SA, Pathak DR, Mettler FA, Key CR, Pike MC (1995) Breast mammographic pattern: a concatenation of confounding and breast cancer risk factors. Am J Epidemiol 142(8):813–819PubMed
20.
Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V (1996) Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 276(1):33–38PubMedCrossRef
21.
Banks E, Reeves G, Beral V et al (2004) Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 329(7464):477PubMedCrossRef
22.
Deglise C, Bouchardy C, Burri M et al (2010) Impact of obesity on diagnosis and treatment of breast cancer. Breast Cancer Res Treat 120(1):185–193PubMedCrossRef
23.
de Waard F, Collette HJ, Rombach JJ, Baanders-van Halewijn EA, Honing C (1984) The DOM project for the early detection of breast cancer, Utrecht, The Netherlands. J Chronic Dis 37(1):1–44PubMedCrossRef
24.
Brekelmans CT, Peeters PH, Faber JA, Deurenberg JJ, Collette HJ (1994) The epidemiological profile of women with an interval cancer in the DOM screening programme. Breast Cancer Res Treat 30(3):223–232PubMedCrossRef
25.
Mandelson MT, Oestreicher N, Porter PL et al (2000) Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 92(13):1081–1087PubMedCrossRef
26.
De Stavola BL, Gravelle IH, Wang DY et al (1990) Relationship of mammographic parenchymal patterns with breast cancer risk factors and risk of breast cancer in a prospective study. Int J Epidemiol 19(2):247–254PubMedCrossRef
27.
Sala E, Warren R, McCann J, Duffy S, Luben R, Day N (2000) High-risk mammographic parenchymal patterns, hormone replacement therapy and other risk factors: a case-control study. Int J Epidemiol 29(4):629–636PubMedCrossRef
28.
Boyd NF, Martin LJ, Sun L et al (2006) Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 15(11):2086–2092PubMedCrossRef
29.
Sung J, Song YM, Stone J, Lee K, Kim SY (2010) Association of body size measurements and mammographic density in Korean women: the healthy twin study. Cancer Epidemiol Biomarkers Prev 19(6):1523–1531PubMedCrossRef
30.
Willett WC, Browne ML, Bain C et al (1985) Relative weight and risk of breast cancer among premenopausal women. Am J Epidemiol 122(5):731–740PubMed
31.
Hankinson SE, Willett WC, Manson JE et al (1995) Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 87(17):1297–1302PubMedCrossRef
32.
Cunningham JE, Butler WM (2004) Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat 88(2):161–176PubMedCrossRef
33.
Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW (2001) Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 92(1):37–45PubMedCrossRef
34.
Shen Y, Costantino JP, Qin J (2008) Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer. J Natl Cancer Inst 100(20):1448–1453PubMedCrossRef
35.
Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA (2000) Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 11(7):653–662PubMedCrossRef
36.
Butler LM, Gold EB, Conroy SM et al (2010) Active, but not passive cigarette smoking was inversely associated with mammographic density. Cancer Causes Control 21(2):301–311PubMedCrossRef
37.
Bremnes Y, Ursin G, Bjurstam N, Gram IT (2007) Different measures of smoking exposure and mammographic density in postmenopausal Norwegian women: a cross-sectional study. Breast Cancer Res 9(5):R73PubMedCrossRef
38.
Brand JS, Chan MF, Dowsett M, et al. (2011) Cigarette Smoking and Endogenous Sex Hormones in Postmenopausal Women. J Clin Endocrinol Metab. doi:10.​1210/​jc.​2011-1165
39.
Pasquali R, Vicennati V, Bertazzo D et al (1997) Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio-Menopause-Health Group. Metabolism 46(1):5–9PubMedCrossRef
40.
Carney PA, Miglioretti DL, Yankaskas BC et al (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138(3):168–175PubMed
41.
Kavanagh AM, Byrnes GB, Nickson C et al (2008) Using mammographic density to improve breast cancer screening outcomes. Cancer Epidemiol Biomarkers Prev 17(10):2818–2824PubMedCrossRef
42.
Olsen AH, Bihrmann K, Jensen MB, Vejborg I, Lynge E (2009) Breast density and outcome of mammography screening: a cohort study. Br J Cancer 100(7):1205–1208PubMedCrossRef
43.
Aiello EJ, Buist DS, White E, Porter PL (2005) Association between mammographic breast density and breast cancer tumor characteristics. Cancer Epidemiol Biomarkers Prev 14(3):662–668PubMedCrossRef
44.
Ghosh K, Brandt KR, Sellers TA et al (2008) Association of mammographic density with the pathology of subsequent breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 17(4):872–879PubMedCrossRef
45.
Australian Institute of Health and Welfare (AIHW) (2005) Breast screen Australia monitoring report 2001–2002. AIHW (Cancer Series no. 29), Canberra
46.
Joensuu H, Lehtimaki T, Holli K et al (2004) Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292(9):1064–1073PubMedCrossRef
47.
Sihto H, Lundin J, Lehtimaki T et al (2008) Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 14(13):4103–4110PubMedCrossRef
48.
Kavanagh AM, Giles GG, Mitchell H, Cawson JN (2000) The sensitivity, specificity, and positive predictive value of screening mammography and symptomatic status. J Med Screen 7(2):105–110PubMedCrossRef
49.
Schousboe JT, Kerlikowske K, Loh A, Cummings SR (2011) Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med 155(1):10–20PubMed
50.
Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L (2009) Screening for breast cancer: an update for the US preventive services task force. Ann Intern Med 151(10):727–742PubMed
51.
Kerlikowske K (2009) Evidence-based breast cancer prevention: the importance of individual risk. Ann Intern Med 151(10):750–752PubMed
Metadata
Title
Bodyweight and other correlates of symptom-detected breast cancers in a population offered screening
Authors
Anne Kricker
Tracey DiSipio
Jennifer Stone
Chris Goumas
Jane E. Armes
Dorota M. Gertig
Bruce K. Armstrong
Publication date
01-01-2012
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 1/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-011-9858-9

Other articles of this Issue 1/2012

Cancer Causes & Control 1/2012 Go to the issue

Original paper

Dual effect of short interval between first and second birth on ductal breast cancer risk in Finland

Original paper

Sun protective behaviors and vitamin D levels in the US population: NHANES 2003–2006

Original Paper

Improved survival among patients with base of tongue and tonsil cancer in the United States

Original paper

Factors associated with mortality after breast cancer metastasis

Original paper

Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica

Original paper

Reproductive factors and lymphoid neoplasms in Europe: findings from the EpiLymph case–control study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits